Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 156-162 , June 2010

Primary cutaneous marginal zone lymphoma

  • Stéphane Dalle

      Affiliations

    • Service de dermatologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
    • Corresponding Author InformationCorresponding author at: Service de Dermatologie, Centre Hospitalier Lyon-Sud, 165 chemin du grand Revoyet, 69495 Pierre Bénite, France. Tel.: +33 478920936; fax: +33 478920939.
    • ,
  • Luc Thomas

      Affiliations

    • Service de dermatologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
    • ,
  • Brigitte Balme

      Affiliations

    • Service de dermatologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
    • ,
  • Charles Dumontet

      Affiliations

    • Hématologie, Université Claude Bernard Lyon I, Hospices Civils de Lyon, Lyon, France
    • ,
  • Catherine Thieblemont

      Affiliations

    • Service d’hémato-oncologie, Hôpital Saint-Louis, Université Paris Diderot 7, Institut Universitaire d’Hématologie, Paris, France

,Accepted 16 September 2009.

References 

  1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410–1416
  2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–18.
  3. Pelstring RJ, Essell JH, Kurtin PJ, et al. Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol. 1991;96:738–745
  4. Bailey EM, Ferry JA, Harris NL, et al. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol. 1996;20:1011–1023
  5. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  6. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology. 1993;23:117–125
  7. Fink-Puches R, Zenahlik P, Back B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer. World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99:800–805
  8. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol. 2002;2:323–335
  9. Pillai S, Cariappa A, Moran ST. Marginal zone B cells. Annu Rev Immunol. 2005;23:161–196
  10. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity. 2001;14:617–629
  11. Weller S, Reynaud CA, Weill JC. Splenic marginal zone B cells in humans: where do they mutate their Ig receptor?. Eur J Immunol. 2005;35:2789–2792
  12. Ferreri AJ, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med. 2009;265:421–438
  13. Jelic S, Filipovic-Ljeskovic I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients, is it a fortuitous finding?. Hematol Oncol. 1999;17:107–116
  14. Goodlad JR, Davidson MM, Hollowood K, et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology. 2000;37:501–508
  15. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000;24:1279–1285
  16. Cerroni L, Zochling N, Putz B, et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24:457–461
  17. Garbe C, Stein H, Dienemann D, et al. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol. 1991;24:584–590
  18. de la Fouchardiere A, Vandenesch F, Berger F. Borrelia-associated primary cutaneous MALT lymphoma in a nonendemic region. Am J Surg Pathol. 2003;27:702–703
  19. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol. 2000;31:263–268
  20. Stanek G, Strle F. Lyme borreliosis. Lancet. 2003;362:1639–1647
  21. Colli C, Leinweber B, Mullegger R, et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol. 2004;31:232–240
  22. Li C, Inagaki H, Kuo TT, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases. Am J Surg Pathol. 2003;27:1061–1069
  23. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28:502–507
  24. Monari P, Farisoglio C, Calzavara Pinton PG. Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. Dermatology. 2007;215:229–232
  25. Bahler DW, Kim BK, Gao A, et al. Analysis of immunoglobulin V genes suggests cutaneous marginal zone B-cell lymphomas recognise similar antigens. Br J Haematol. 2006;132:571–575
  26. Kutting B, Bonsmann G, Metze D, et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997;36:311–314
  27. Nihal M, Mikkola D, Horvath N, et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol. 2003;34:617–622
  28. Grange F, Wechsler J, Guillaume JC, et al. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol. 2002;47:530–534
  29. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034–3044
  30. Fink-Puches R, Chott A, Ardigo M, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol. 2004;21:525–533
  31. Dargent JL, Devalck C, De Mey A, et al. Primary cutaneous marginal zone B-cell lymphoma of MALT type in a child. Pediatr Dev Pathol. 2006;9:468–473
  32. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24:1376–1382
  33. Bathelier E, Thomas L, Balme B, et al. Marginal zone B-cell lymphoma affecting the skin: histological and phenotypic study of 49 cases. Ann Dermatol Venereol. 2008;135:748–752
  34. Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147:1147–1158
  35. Cho-Vega JH, Vega F, Rassidakis G, et al. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol. 2006;125(Suppl.):S38–S49
  36. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol. 2003;149:1183–1191
  37. de Leval L, Harris NL, Longtine J, et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol. 2001;25:732–741
  38. Gallardo F, Bellosillo B, Espinet B, et al. Aberrant nuclear BCL10 expression and lack of t(11, 18)(q21, q21) in primary cutaneous marginal zone B-cell lymphoma. Hum Pathol. 2006;37:867–873
  39. van Maldegem F, van Dijk R, Wormhoudt TA, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood. 2008;112:3355–3361
  40. Streubel B, Lamprecht A, Dierlamm J, et al. T(14, 18)(q32, q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335–2339
  41. Streubel B, Vinatzer U, Lamprecht A, et al. T(3, 14)(p14.1, q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19:652–658
  42. Deutsch AJ, Fruhwirth M, Aigelsreiter A, et al. Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation. J Invest Dermatol. 2008;
  43. Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008;451:841–845
  44. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet. 2008;40:108–112
  45. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341–346
  46. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood. 2003;102:1833–1841
  47. Dijkman R, Tensen CP, Buettner M, et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood. 2006;107:4926–4929
  48. Bodor C, Bognar A, Reiniger L, et al. Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br J Haematol. 2005;129:373–376
  49. Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood. 2007;109:3500–3504
  50. Halldorsdottir AM, Fruhwirth M, Deutsch A, et al. Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma. Leuk Res. 2008;32:1015–1021
  51. Gronbaek K, Ralfkiaer E, Kalla J, et al. Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11, 18) in primary cutaneous MALT-type lymphoma. J Pathol. 2003;201:134–140
  52. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol. 2004;123:213–219
  53. Espinet B, Gallardo F, Pujol RM, et al. Absence of MALT1 translocations in primary cutaneous marginal zone B-cell lymphoma. Haematologica. 2004;89:ELT14
  54. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11:285–291
  55. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802–806
  56. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489–2495
  57. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479–484
  58. Bathelier E, Thomas L, Balme B, et al. Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. Br J Dermatol. 2008;159:498–500
  59. Senff NJ, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol. 2008;142:52–56
  60. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol. 2005;23:6415–6420
  61. Grunberger B, Wohrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol. 2006;24:1370–1375
  62. Dreno B. Standard and new treatments in cutaneous B-cell lymphomas. J Cutan Pathol. 2006;33(Suppl. 1):47–51
  63. Zenahlik P, Fink-Puches R, Kapp KS, et al. Therapy of primary cutaneous B-cell lymphomas. Hautarzt. 2000;51:19–24
  64. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141:1139–1145
  65. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112:1600–1609
  66. Thieblemont C, Coiffier B. Management of marginal zone lymphomas. Curr Treat Options Oncol. 2006;7:213–222
  67. Senff NJ, Hoefnagel JJ, Neelis KJ, et al. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol. 2007;143:1520–1526
  68. Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma. 2006;47:865–869
  69. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–2745
  70. Valencak J, Weihsengruber F, Rappersberger K, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol. 2008;
  71. Gellrich S, Muche JM, Wilks A, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas—an applicational observation. Br J Dermatol. 2005;153:167–173
  72. Soda R, Costanzo A, Cantonetti M, et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol. 2001;81:207–208
  73. Kyrtsonis MC, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77:300–303
  74. Kerl K, Prins C, Saurat JH, et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol. 2006;155:1197–1200
  75. Gronbaek K, Moller PH, Nedergaard T, et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol. 2000;142:913–923
  76. Sah A, Barrans SL, Parapia LA, et al. Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol. 2004;75:195–199
  77. Stanway A, Rademaker M, Kennedy I, et al. Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil. Aust J Dermatol. 2004;45:110–113

PII: S1040-8428(09)00180-2

doi: 10.1016/j.critrevonc.2009.09.003

Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 156-162 , June 2010

Article Tools

* Image Usage & Resolution